(non-)Hodgkin lymphoma and cervical cancer breast cancer cancer: including leukemia Ewing sarcoma osteosarcoma testicular cancer
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Aged 18-39 years at cancer diagnosis - Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer. - Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.
Exclusion criteria
Exclusion criteria: - who are not able to understand the patient information letter and informed consent form - who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis - who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is change in senescence marker P16 between start of systemic therapy and one year later. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are: Changes in senescence-associated secretory phenotype (SASP) and vascular markers; prevalence of classical cardiovascular risk factors (lipids, BMI, glucose); tumour (treatment), patient (age, sex, pre-existent cardiometabolic status), and sociodemographic (lifestyle) factors related to the changes in senescence, SASP and cardiovascular risk factors. | — |
Countries
Netherlands
Outcome results
None listed